Differential effects of WRAP53 transcript variants on non-small cell lung cancer cell behaviors

Background The WD40-encoding RNA antisense to p53 (WRAP53) is an antisense gene of TP53 with three transcriptional start sites producing three transcript variants involved in the progression of non-small cell lung cancer. However, the mechanism by which these different transcript variants regulate non-small cell lung cancer cell behaviors is to be elucidated. Methods Two non-small cell lung cancer cell lines, A549 cells with wild-type p53 and H1975 with mutated p53, were transfected with WRAP53-1α and WRAP53-1β siRNA. The biological effects were assessed via colony formation, cell viability, apoptosis, cell cycle, wound healing and cell invasion assays, as well as immunoblotting. Results Knockdown of WRAP53-1α increased the mRNA and protein levels of p53; suppressed colony formation and proliferation of A549 cells but promoted them in H1975 cells; increased the proportion of cells in the G0/G1 phase in A549 cells but decreased that in H1975 cells; and suppressed migration and invasion in A549 cells but not in H1975 cells. Conversely, knockdown of WRAP53-1β had no effect on p53 expression; promoted the growth of A549 cells but not of H1975 cells; decreased the proportion of cells in the G0/G1 phase in A549 cells but not in H1975 cells; and promoted migration and invasion in A549 cells but not in H1975 cells. Knockdown of both WRAP53-1α and WRAP53-1β promoted apoptosis in A549 cells but not in H1975 cells. Conclusions WRAP53 transcript variants exerted different functions in non-small cell lung cancer cells and regulated non-small cell lung cancer cell behaviors depending on the p53 expression.

[1]  Davoud Farajzadeh,et al.  Haplotype and linkage disequilibrium of TP53-WRAP53 locus in Iranian-Azeri women with breast cancer , 2019, PloS one.

[2]  S. Fan,et al.  Expression of WDR79 is associated with TP53 mutation and poor prognosis in surgically resected non-small cell lung cancer , 2019, Journal of Cancer.

[3]  Wang-Yu Zhu,et al.  Prognostic value of mutant p53, Ki-67, and TTF-1 and their correlation with EGFR mutation in patients with non-small cell lung cancer. , 2019, Histology and histopathology.

[4]  I. Berindan‐Neagoe,et al.  The Function of Non-Coding RNAs in Lung Cancer Tumorigenesis , 2019, Cancers.

[5]  H. Chander,et al.  Awakening the “guardian of genome”: reactivation of mutant p53 , 2018, Cancer Chemotherapy and Pharmacology.

[6]  Dong Sun Kim,et al.  Promoter methylation of Wrap53α, an antisense transcript of p53, is associated with the poor prognosis of patients with non-small cell lung cancer , 2018, Oncology letters.

[7]  L. Ding,et al.  Oncogenic Activity of Wrap53 in Human Colorectal Cancer In Vitro and in Nude Mouse Xenografts , 2018, Medical science monitor : international medical journal of experimental and clinical research.

[8]  X. Jiao,et al.  The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer, an analysis based on cBioPortal data base. , 2018, Lung cancer.

[9]  K. Wiman,et al.  Correction: WRAP53 Is Essential for Cajal Body Formation and for Targeting the Survival of Motor Neuron Complex to Cajal Bodies , 2018, PLoS biology.

[10]  B. P. Jain,et al.  WD40 Repeat Proteins: Signalling Scaffold with Diverse Functions , 2018, The Protein Journal.

[11]  H. Sabe,et al.  p53-Dependent and -Independent Epithelial Integrity: Beyond miRNAs and Metabolic Fluctuations , 2018, Cancers.

[12]  W. Xiong,et al.  WDR79 mediates the proliferation of non‐small cell lung cancer cells by regulating the stability of UHRF1 , 2018, Journal of cellular and molecular medicine.

[13]  Wenwei Hu,et al.  Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy. , 2017, Journal of molecular biology.

[14]  Chao Yang,et al.  WDR79 promotes the proliferation of non-small cell lung cancer cells via USP7-mediated regulation of the Mdm2-p53 pathway , 2017, Cell Death & Disease.

[15]  X. Hua,et al.  Somatic Genomics and Clinical Features of Lung Adenocarcinoma: A Retrospective Study , 2016, PLoS medicine.

[16]  Mao Ye,et al.  Overexpression of WDR79 in non‐small cell lung cancer is linked to tumour progression , 2016, Journal of cellular and molecular medicine.

[17]  M. Sallam,et al.  Investigation of long noncoding RNAs expression profile as potential serum biomarkers in patients with hepatocellular carcinoma. , 2016, Translational research : the journal of laboratory and clinical medicine.

[18]  C. Méndez-Vidal,et al.  Wrap53, a Natural p53 Antisense Transcript Required for p53 Induction upon DNA Damage. , 2016, Molecular cell.

[19]  K. Jirström,et al.  Downregulation of the cancer susceptibility protein WRAP53β in epithelial ovarian cancer leads to defective DNA repair and poor clinical outcome , 2015, Cell Death and Disease.

[20]  M. Farnebo,et al.  On the road with WRAP53β: guardian of Cajal bodies and genome integrity , 2015, Front. Genet..

[21]  K. Roberg,et al.  Nuclear expression of WRAP53β is associated with a positive response to radiotherapy and improved overall survival in patients with head and neck squamous cell carcinoma. , 2015, Oral oncology.

[22]  B. Zhivotovsky,et al.  The scaffold protein WRAP53β orchestrates the ubiquitin response critical for DNA double-strand break repair , 2014, Genes & development.

[23]  V. Montazeri,et al.  Single-strand conformational polymorphism analysis of a common single nucleotide variation in WRAP53 gene, rs2287499, and evaluating its association in relation to breast cancer risk and prognosis among Iranian-Azeri population , 2014, Medical Oncology.

[24]  Ping Zhang,et al.  TCAB1: a potential target for diagnosis and therapy of head and neck carcinomas , 2014, Molecular Cancer.

[25]  Xuhong Song,et al.  Overexpression of WRAP53 Is Associated with Development and Progression of Esophageal Squamous Cell Carcinoma , 2014, PloS one.

[26]  J. Bourdon,et al.  Uncovering the role of p53 splice variants in human malignancy: a clinical perspective , 2013, OncoTargets and therapy.

[27]  S. Kouhsari,et al.  Overlapping region of p53/wrap53 transcripts: mutational analysis and sequence similarity with microRNA-4732-5p. , 2013, Asian Pacific journal of cancer prevention : APJCP.

[28]  J. Lubiński,et al.  Association of common WRAP 53 variant with ovarian cancer risk in the Polish population , 2012, Molecular Biology Reports.

[29]  Yan Wang,et al.  Long non-coding RNAs: versatile master regulators of gene expression and crucial players in cancer. , 2012, American journal of translational research.

[30]  M. Dobbelstein,et al.  Anthracyclines induce the accumulation of mutant p53 through E2F1-dependent and -independent mechanisms , 2011, Oncogene.

[31]  S. Mahmoudi,et al.  WRAP53 promotes cancer cell survival and is a potential target for cancer therapy , 2011, Cell Death and Disease.

[32]  Jian Kang,et al.  Cisplatin induces apoptosis via upregulating Wrap53 in U-2OS osteosarcoma cells. , 2011, Asian Pacific journal of cancer prevention : APJCP.

[33]  T. Myers,et al.  Disruption of telomerase trafficking by TCAB1 mutation causes dyskeratosis congenita. , 2011, Genes & development.

[34]  A. Werner,et al.  What are natural antisense transcripts good for? , 2010, Biochemical Society transactions.

[35]  D. Green,et al.  Cytoplasmic functions of the tumour suppressor p53 , 2009, Nature.

[36]  J. Steitz,et al.  A conserved WD40 protein binds the Cajal body localization signal of scaRNP particles. , 2009, Molecular cell.

[37]  Timothy D. Veenstra,et al.  A Human Telomerase Holoenzyme Protein Required for Cajal Body Localization and Telomere Synthesis , 2009, Science.

[38]  Robert Welch,et al.  Common genetic variation in TP53 and its flanking genes, WDR79 and ATP1B2, and susceptibility to breast cancer , 2007, International journal of cancer.

[39]  J. Venables Unbalanced alternative splicing and its significance in cancer , 2006, BioEssays : news and reviews in molecular, cellular and developmental biology.

[40]  D. Black Mechanisms of alternative pre-messenger RNA splicing. , 2003, Annual review of biochemistry.